import { Drug } from '@/types';

export const moodStabilizersData: Drug[] = [
  {
    id: 'lithium',
    name: 'Lithium',
    class: 'Mood Stabilizer',
    mechanism: 'Exact mechanism unclear. Modulates neurotransmitter systems, affects second messenger systems, and has neuroprotective properties.',
    indications: [
      'Bipolar disorder (acute mania and maintenance)',
      'Augmentation in treatment-resistant depression',
      'Cluster headache prophylaxis (off-label)',
    ],
    contraindications: [
      'Severe renal impairment',
      'Severe cardiovascular disease',
      'Dehydration/sodium depletion',
    ],
    sideEffects: [
      'Tremor (fine hand tremor)',
      'Polyuria and polydipsia (nephrogenic DI)',
      'Weight gain',
      'Hypothyroidism',
      'GI upset (nausea, diarrhea)',
      'Cognitive dulling',
      'Acne',
      'Edema',
      'Lithium toxicity at high levels',
    ],
    interactions: [
      'NSAIDs: Increase lithium levels',
      'Thiazide diuretics: Increase lithium levels',
      'ACE inhibitors: Increase lithium levels',
      'Dehydration: Increases toxicity risk',
    ],
    monitoring: [
      'Serum lithium levels (trough: 0.6-1.2 mEq/L)',
      'Renal function (baseline and q6-12 months)',
      'Thyroid function (baseline and q6-12 months)',
      'Calcium (baseline)',
      'ECG in elderly or cardiac history',
      'Weight',
    ],
    dosing: {
      starting: '300 mg BID-TID',
      therapeutic: '900-1800 mg daily in divided doses',
      maximum: 'Based on levels, not fixed dose',
    },
    switchingNotes: [
      'Do not abruptly discontinue (rebound mania risk)',
      'Taper over weeks to months',
      'Can be combined with other mood stabilizers or antipsychotics',
    ],
    warnings: [
      'Narrow therapeutic index (0.6-1.2 mEq/L)',
      'Toxicity signs: coarse tremor, confusion, ataxia, seizures, arrhythmias',
      'Teratogenic (Ebstein anomaly)',
      'Long-term: risk of chronic kidney disease and hypothyroidism',
    ],
    specialPopulations: {
      pregnancy: 'Category D. Risk of Ebstein anomaly. Avoid in first trimester if possible.',
      lactation: 'Excreted in breast milk; generally contraindicated.',
      geriatric: 'Lower doses; more susceptible to toxicity.',
      renal: 'Contraindicated in severe impairment; dose reduction in mild-moderate.',
      hepatic: 'No hepatic metabolism; no adjustment needed.',
    },
  },
  {
    id: 'valproate',
    name: 'Valproate (Divalproex)',
    class: 'Mood Stabilizer / Anticonvulsant',
    mechanism: 'Increases GABA availability, blocks voltage-gated sodium channels. Multiple mechanisms.',
    indications: [
      'Bipolar disorder (acute mania)',
      'Epilepsy',
      'Migraine prophylaxis',
    ],
    contraindications: [
      'Hepatic disease',
      'Urea cycle disorders',
      'Pregnancy (highly teratogenic)',
      'Mitochondrial disorders',
    ],
    sideEffects: [
      'GI upset',
      'Weight gain',
      'Tremor',
      'Sedation',
      'Hair loss (alopecia)',
      'Thrombocytopenia',
      'Hepatotoxicity',
      'Pancreatitis (rare)',
      'Polycystic ovary syndrome (PCOS) risk',
    ],
    interactions: [
      'Hepatotoxic drugs',
      'Enzyme inhibitor: increases levels of lamotrigine, phenobarbital, others',
      'Additive CNS depression with sedatives',
    ],
    monitoring: [
      'Liver function tests (baseline and periodically)',
      'CBC with platelets',
      'Valproate levels (therapeutic: 50-125 µg/mL)',
      'Ammonia if encephalopathy suspected',
      'Weight',
    ],
    dosing: {
      starting: '250 mg BID',
      therapeutic: '750-2000 mg daily in divided doses',
      maximum: 'Based on levels and response',
    },
    switchingNotes: [
      'Taper gradually',
      'Can combine with lithium or antipsychotics',
      'Increases lamotrigine levels (double the rash risk)',
    ],
    warnings: [
      'Black box: Hepatotoxicity, pancreatitis, teratogenicity',
      'Highly teratogenic: neural tube defects, decreased IQ in offspring',
      'Avoid in women of childbearing potential if possible',
    ],
    specialPopulations: {
      pregnancy: 'Category D/X. Highly teratogenic. Avoid if at all possible.',
      lactation: 'Excreted in milk; weigh risks/benefits.',
      geriatric: 'Lower doses; monitor for sedation.',
      renal: 'Protein binding altered in renal failure; caution.',
      hepatic: 'Contraindicated.',
    },
  },
  {
    id: 'carbamazepine',
    name: 'Carbamazepine',
    class: 'Mood Stabilizer / Anticonvulsant',
    mechanism: 'Blocks voltage-gated sodium channels. Mood stabilizing properties.',
    indications: [
      'Bipolar disorder (acute mania, maintenance)',
      'Epilepsy (partial and generalized tonic-clonic seizures)',
      'Trigeminal neuralgia',
    ],
    contraindications: [
      'Bone marrow suppression',
      'Concurrent MAOI use',
      'HLA-B*1502 allele (in Asian populations)',
    ],
    sideEffects: [
      'Dizziness, ataxia',
      'Sedation',
      'Nausea',
      'Diplopia, blurred vision',
      'Hyponatremia (SIADH)',
      'Rash (including Stevens-Johnson syndrome risk)',
      'Leukopenia, aplastic anemia (rare)',
    ],
    interactions: [
      'Strong CYP3A4 inducer: decreases levels of many drugs (OCPs, warfarin, etc.)',
      'Autoinduction: induces own metabolism',
      'Decreases lamotrigine levels',
    ],
    monitoring: [
      'CBC with differential (baseline, frequent early, then periodic)',
      'Liver function tests',
      'Sodium levels',
      'Carbamazepine levels (therapeutic: 4-12 µg/mL)',
      'Genetic testing (HLA-B*1502) in at-risk populations before initiation',
    ],
    dosing: {
      starting: '200 mg BID',
      therapeutic: '800-1200 mg daily in divided doses',
      maximum: '1600 mg daily',
    },
    switchingNotes: [
      'Autoinduction occurs over 3-5 weeks',
      'May need dose adjustment due to enzyme induction',
      'Taper gradually to avoid seizure risk',
    ],
    warnings: [
      'Black box: Aplastic anemia, agranulocytosis, serious dermatologic reactions (SJS/TEN)',
      'HLA-B*1502 screening recommended in Asian populations before starting',
      'Strong enzyme inducer affects many medications',
    ],
    specialPopulations: {
      pregnancy: 'Category D. Risk of neural tube defects.',
      lactation: 'Excreted in milk; use caution.',
      geriatric: 'Increased risk of hyponatremia and falls.',
      renal: 'Caution; monitor levels.',
      hepatic: 'Contraindicated in hepatic disease.',
    },
  },
  {
    id: 'lamotrigine',
    name: 'Lamotrigine',
    class: 'Mood Stabilizer / Anticonvulsant',
    mechanism: 'Blocks voltage-gated sodium channels, inhibits glutamate release. More effective for bipolar depression than mania.',
    indications: [
      'Bipolar disorder (maintenance, especially prevention of depressive episodes)',
      'Epilepsy',
    ],
    contraindications: [
      'Hypersensitivity to lamotrigine',
    ],
    sideEffects: [
      'Rash (including risk of Stevens-Johnson syndrome)',
      'Headache',
      'Dizziness',
      'Nausea',
      'Insomnia',
      'Generally well tolerated',
    ],
    interactions: [
      'Valproate: Doubles lamotrigine levels (must halve lamotrigine dose)',
      'Carbamazepine, phenytoin: Decrease lamotrigine levels',
      'Oral contraceptives: Decrease lamotrigine levels',
    ],
    monitoring: [
      'Rash (especially during titration)',
      'Mood symptoms',
      'No routine labs required',
    ],
    dosing: {
      starting: '25 mg daily x 2 weeks, then slow titration (slower if on valproate)',
      therapeutic: '100-400 mg daily',
      maximum: '400 mg daily (monotherapy); 200 mg with valproate',
    },
    switchingNotes: [
      'SLOW titration essential to reduce rash risk',
      'If stopped for >5 days, must re-titrate from beginning',
      'Valproate requires halving lamotrigine dose',
    ],
    warnings: [
      'Black box: Serious rashes including SJS/TEN',
      'Risk highest in first 8 weeks, with rapid titration, or in children',
      'Stop immediately if rash develops',
    ],
    specialPopulations: {
      pregnancy: 'Category C. Relatively safer than valproate.',
      lactation: 'Present in milk; weigh benefits/risks.',
      geriatric: 'Lower doses may be sufficient.',
      renal: 'Reduce dose in severe impairment.',
      hepatic: 'Reduce dose in moderate-severe impairment.',
    },
  },
];
